Beerse (Belgium), 20th May 2019 – OCTIMET Oncology, a clinical-stage biotech company with a focus on the development of highly specific and differentiated oral kinase inhibitors, announces the appointment of Shelley Margetson as CEO. Timothy Perera PhD, founder of the company, will continue as CSO.
“Shelley brings a skill set that very much complements and strengthens the existing management team in keeping with current stage of the company. We are grateful to Tim for bringing the company so far and are looking forward to the team progressing the company further” says Christina Takke from V-Bio Ventures.
“I am excited to join OCTIMET at its current phase of development and to work closely with its extremely experienced management team,” said Ms. Margetson. “The company has made significant progress in advancing its lead compound in the clinic as a single agent, and will be commencing combination clinical trials later this year. I look forward to guiding the company towards its next milestones, including new fundraising activities.”
Shelley Margetson is an experienced biotech business executive. Prior to joining OCTIMET, she was the CEO of Gadeta, where she oversaw the closing of a strategic collaboration with Kite, a Gilead company, in 2018 which gave Kite the exclusive option to acquire Gadeta. Previously, Shelley was CFO at Merus (NASDAQ: MRUS) where she was involved in raising over EUR 100 million in private financing from venture capital and big pharma corporate investors and played a pivotal role in their initial public listing on the Nasdaq in May 2016. Ms Margetson has worked in various European biotech companies for close to twenty years.
About OCTIMET OCTIMET Oncology NV acts as a translational accelerator, focusing on creating value for patients and investors by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centred biomarker approaches. OCTIMET was set-up in 2016 and is backed by leading national and international life sciences investors. OCTIMET licensed three patent families related to highly selective MET kinase inhibitors from Janssen Pharmaceutical companies of Johnson and Johnson in January 2017. OCTIMET is based at the JLABS @ BE facility in Beerse (Belgium). The current focus is on its clinical stage lead asset OMO-1, a highly selective small molecule MET kinase inhibitor that is developed using specific patient selection biomarkers.
Shelley Margetson, CEO, OCTIMET Oncology NV
Telephone: +31 (0) 631 900 812 - E-Mail: - www.octimet.com